evotec

#RESEARCHNEVERSTOPS



AI/ML Precision Technologies driving Probabilities of Success up (PoS up)

Cautionary statement regarding forward-looking statements

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “goal”, “intend”, “look forward to”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “will”, “would” and similar expressions. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements.

evotec

#RESEARCHNEVERSTOPS

PoS up

AI/ML Precision Technologies driving Probabilities of Success up (PoS up)

Capital Markets Day, 02 March 2022

8.00 am EST – 10.30 am EST; 2.00 pm CET / 1.00 pm GMT

AGENDA

▶ **08.00 – 08.15 am**	**Action Plan 2025 update - "…just the beginning" of the data-driven R&D Autobahn to Cures**
▶ **08.15 – 09.15 am**	**Precision technologies bring PoS up** **From molecular databases via iPSCs, to AI/ML tools at work**
▶ 09.15 – 09.20 am	*Short Break – Q&A*
▶ **09.20 – 10.10 am**	**Integrated processes bring PoS up** **From targets, via full suite of AI/ML tools, to manufacturing**
▶ **10.10 – 10.30 am**	**Roundup & Q&A session**

The recorded webcast will be available as of the next day.

Let’s talk about Probabilities of Success

1st Capital Markets Day 2022

Werner Lanthaler
CEO

Cord Dohrmann
CSO

Craig Johnstone
COO

Uwe Andag
Metabolic Diseases

Christiane Honisch
Diagnostics & Stratification

Nele Schwarz
Stem Cell & Regenerative Biology

Paul Walker
Toxicology & Innovation Efficiency

Linda Zuckerman
Biotherapeutics

Steffen Grimm
RNA

Agenda

Action Plan 2025 update
"…just the beginning" of the data-driven R&D Autobahn to Cures

Precision technologies bring PoS up
From molecular databases via iPSCs, to AI/ML tools at work

Processes bring PoS up
From targets, via full suite of AI/ML tools, to manufacturing

Roundup & Q&A session



Bringing the industry closer together

Our contribution to the industry



„The goal of Evolution is not one single human, it is mankind.“

Manfred Eigen
1927–2019, Co-founder of Evotec,
Nobel Prize 1967

We discover medicines for difficult to treat diseases in **efficient collaborations**

We focus on data driven precision medicine and early disease relevance to **improve Probabilities of Success**

We built the “shared economy” in R&D, designed to result in **a large royalty pool**

AP 2025 is fully in swing and accelerated by precision medicine

Action Plan in numbers

2009 | 2012 | 2018 | 2021 | 2025

Action Plan 2012
Restructure for growth

2010
- Revenues: € 55 m
- Adj. EBITDA: € 2 m
- R&D investments:[1] € 2 m
- Co-owned projects: 6
- Employees: 519

Action Plan 2016
Build innovation seeds

2015
- Revenues: € 128 m
- Adj. EBITDA: € 9 m
- R&D investments:[1] € 18 m
- Co-owned projects: 49
- Employees: 1,000

Action Plan 2022
Aspire global leadership

2020
- Revenues: € 501 m
- Adj. EBITDA: € 107 m
- R&D investments:[1] € 69 m
- Co-owned projects[2]: 118
- Employees: 3,572

Action Plan 2025
Leadership in data, science, multimodality & access



ACTION PLAN 2025
The data-driven R&D Autobahn to Cures

2025
- Revenues: > € 1 bn
- Adj. EBITDA: > € 300 m
- R&D investments[1]: >> € 100 m
- Co-owned projects: > 170
- Employees; > 5,000

[1] Including equity investments
[2] Does not include EVT equity investments

Our Innovation hub is high-tech driven and fully integrated

Capabilities & expertise overview

Industry needs

R&D efficiency platforms[1)]

Precision medi-cine platforms

Just – Evotec Biologics[1)]

Right modality drug design

Capabilities & Expertise (illustrative)

- Target ID & validation
- Hit identification
- Lead optimisation
- Sample management
- Chemistry
- DMPK & ADME-Tox
- Research informatics
- Bio Reagents
- *In vitro* biology
- *In vivo* Pharmacology
- Biomarker discovery
- Antibody discovery
- INDiGO
- Integrated CMC
- Integrated pre-clinical development
- Clinical development solution

EVO*panOmics*

EVO*panHunter*

EVO*gnostic*

iPSC Drug Discovery

ScreenSeq HIGH-THROUGHPUT TRANSCRIPTOMICS

ScreenPep HIGH-THROUGHPUT PROTEOMICS

E.MPD TRANSLATIONAL MOLECULAR PATIENT DATABASE

J.DISCOVERY™ MOLECULE DISCOVERY

J.HAL℠ AI DESIGNED mAB LIBRARY

J.MD™ MOLECULE DESIGN

JP3® PROCESS & PRODUCT DESIGN

J.POD® MANUFACTURING DESIGN

EVO*cells*

EVO*genes*

Antibodies & Bifunctionals

Small molecules

Protein degradation

Antisense

Exosomes

E.RNA TARGETING RNA SPACE

E.INVENT-AI MOLECULAR DESIGN EXCELLENCE

[1)] Also partly accessible as stand alone “Fee for Service” or FTE-rate based offerings

Faster and more learning curves illustrate … “just the beginning”

“Evotec inside” (selected KPI’s 2020/21)

62
Patent applications

142
High-throughput screens

12
Pre-clinical development candidates (PDC)

24
INDiGO® programs

> 250
GMP API batches

>10
Precision platforms

>200 bn
Data points

>440 bn
of iPSC-derived cells

>10,000
compounds assessed as protein degraders

>100
EVO*PanHunter* projects

>15
Biologics projects

20
Months construction time

>40,000
samples in HT analytics and functional characterisation

>20
consecutive successful manufacturing runs

>90%
J.POD® cGMP qualification activities completed

>130
Co-owned pipeline assets

>90
Small molecules

>20
Biologics

>10
Cell & gene therapy

>10
Multiple modalities

Despite P2X3 set back; Strategy for royalty pool is fully intact

Steady stream of high-value catalysts

Selected pipeline events within next 12 – 24 months

- Phase III & registration (CHN) JingXin in insomnia (EVT201)
- Phase II initiation with Bayer in DNP (BAY2395840)
- Phase II data with Bayer in DNP (BAY2395840)
- Phase II initiation with Bayer in Gynaecology (BAY2395840)
- Phase I data in Chikungunya virus (EVT894)
- Phase I data with BMS in CNS (EVT8683)
- Phase I data with Exscientia in Oncology (EXS21546)
- Phase I data with Kazia in Oncology (EVT801)
- Phase I initiation in Covid-19 / HBV (EVT075)
- Phase I Initiation with Bayer in Kidney diseases
- Phase I Initiation with Kidney diseases with other partners
- Phase I initiation with BMS in CNS
- Phase I Initiation with BMS in Oncology
- Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, …)

	Molecule	Therapeutic Area/Indication	Partner	Discovery	Pre-clinical	Phase I	Phase II	Phase III
Clinical	EVT201	Insomnia (GABA-A)	京新药业					
	Not Disclosed	Infectious Disease (Antibody)*	SK bioscience					
	BAY2395840	Diabetic Neuropathic Pain (B1)	Bayer					
	CT7001	Oncology (CDK7)	Carrick Therapeutics					
	XP-105	Oncology (mTORC1/2)	Xynomic Pharma					
	EVT401	Immunology & Inflammation (P2X7)	康恩贝集团 CONBA GROUP					
	BAY2328065	Gynaecology	Bayer					
	EXS21546	Oncology (various programmes)	Exscientia					
	CNTX 6016	Pain (CB2)	CENTREXION Therapeutics					
	EVT894	Chikungunya (Antibody)	NIH / SANOFI					
	Not Disclosed	Neuroscience & Pain	n.a.					
	Not Disclosed	Neuroscience & Pain	n.a.					
	EVT801	Oncology (VEGFR3)	KAZIA Therapeutics					
	EVT8683	Neurodegeneration (eIF2b activator)	Bristol Myers Squibb					
	TPM203	Pemphigus Vulgaris (ND)	Topas Therapeutics					
	CT7001	Oncology (CDK7)	Carrick Therapeutics					
	CT7001	Oncology (CDK7)	Carrick Therapeutics					
Pre-clinical	APN411	Oncology – Immunotherapy	SANOFI / APEIRON BIOLOGICS					
	GLPGxxxx	Fibrosis (not disclosed)	Galapagos					
	BAYxxxx	Nephrology (not disclosed)	Bayer					
	QRB001	Metabolic – Diabetes (not disclosed)	QRbeta Therapeutics					
	EVT075	Covid-19 / HBV	n.a.					
	Not disclosed	Various programmes	Bristol Myers Squibb					
	EVTxxxx	CNS, Metabolic, Pain, …	**>10 further programmes**					
Discovery	**Multiple programmes across nephrology, oncology, immunology among other therapeutic areas**							

DNP: Diabetic neuropathic pain
CNS: Central nervous system

The iceberg of our product opportunities

In total > 200 proprietary projects with big financial upside



[1)] Also includes Women's Health, Respiratory projects
The Equity Pipeline does not contain programs from EVT/partners that are not publicly disclosed

Building a massive co-owned clinical pipeline

EVT Innovate pipeline evolution 2015-2025 (e)

2015[3)]
# of projects



2022[1,3)]
# of projects



2025 (e)[2,3)]
# of projects



[1)] As of February 2022; does neither include eliapixant nor projects that were completely stopped, e.g. Diap277, EVT302
[2)] Not risk adjusted
[3)] Does not include EVT equity investments

Building co-owned product upside with limited financial risk

Co-ownership business model 2010-2025 (e)

in products / in € m



1) without EVT Equity

Clear strategy in place

Growth and investment strategy overview – Action Plan 2025

Targeted revenue development

(in € m)



Revenue composition 2020



≥2x

Goal revenue composition



- Composition of revenue mix expected to change over time while ALL fields continue to grow
- Shifting to even more favourable revenue mix expected to drive increased profitability
- Just – Evotec Biologics growth driven by use of J.POD® manufacturing
- First small royalties from pipeline assets expected in 2025

[1)] Just – Evotec Biologics reports under the EVT Execute segment

“To improve IRR we have to integrate tech-driven decisions in discovery. Getting PoS up is Evotec’s key contribution to the sharing economy in R&D.“

Werner Lanthaler

Integrating and accelerating better data for more precise medicine

What does ‘data-driven’ mean in practice?

Multiple sources to drive innovation

- AI-enabled small molecules
- RNA analytics
- Single cell tech-nologies
- Linking genetic, Structures & Functions
- Molecular databases
- Safety prediction
- AI-derived biologics
- Cell Tx
- Quantum simulation
- iPSCs
- Mass Spectro-metry
- Spatial multi-Omics
- CRISPR-based Dx/Tx
- Gene Tx
- Small molecule RNA-binders

R&D efficiency platforms — **EVO*iR&D***

Precision medicine platforms — **EVO*panOmics*** & **EVO*panHunter***

Just – Evotec Biologics — **EVO*access***

Right modality drug design — **EVO*modality***



Still a highly fragmented industry

Selected AI/ML companies (Industry landscape – Illustrative & highly simplified)

Many players at work to initiate a new “data driven” industry paradigm



PoS up is key leverage for better IRR

Current challenges in R&D

Key challenges

R&D model is inefficient	*Challenging returns due to "too late and "expensive failure"*
"One drug fits all" is outdated	*90% of drugs are efficacious only in 50% of patients*
New modalities did not solve all problems	*9% of Phase I biologics receive approval[1)]*
Emerging technologies are still very fragmented	*Precision medicine toolkit, OMICS platforms, and AI/ML*

Development costs per asset increase

Cost per asset doubled since 2010, in US$ m



PoS up

Commercial returns decrease

IRR since 2010



[1)] https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2021/files/reports/2021-clinical-development-success-rates-2011-2020-v17.pdf

[2] excl. Covid-19 vaccines

Sources: Deloitte – Centre for Health Solutions: Ten years on measuring the return of pharmaceutical innovation 2020; Evaluate Pharma – World Preview 2018 / World Preview 2020

Significant improvements of PoS are possible

How we can improve PoS in early R&D **(Examples/simplified)**

Todays use of AI/ML

Target identification

System biology to better understand diseases
e.g. associating existing targets with new diseases

Lead optimisation

In silico classification of targets via computational chemistry e.g. better prioritised drugs accelerated

Trial design

Understanding sub populations via biomarkers
e.g. better patient stratification



Agenda

Action Plan 2025 update
"…just the beginning" of the data-driven R&D Autobahn to Cures

Precision technologies bring PoS up
From molecular databases via iPSCs, to AI/ML tools at work

Processes bring PoS up
From targets, via full suite of AI/ML tools, to manufacturing

Roundup & Q&A session



“AI/ML driven data analysis based on high quality data is the key to improving probabilities of success.“

Cord Dohrmann

Increasing the probability of success is the key challenge

Attrition rates have not improved Selected KPIs

False discovery rate in the pre-clinic[1)]

~95 %

Clinical attrition up to market launch[2)]

> 92 %

Post-market safety events of FDA-approved drugs[3)]

>32 %

Development cost per NME launch[4)]

>$ 3 bn

1) Hingorani, A.D., Kuan, V., Finan, C. et al. Improving the odds of drug development success through human genomics: modelling study. Sci Rep 9, 18911 (2019). https://doi.org/10.1038/s41598-019-54849-w
2) BIO, QLS Advisors, Informa UK Ltd: Clinical Development Success Rates and Contributing Factors 2011–2020, February 2021.
3) Downing NS, et al. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration. JAMA. 2017;317(18):1854–1863. doi:10.1001/jama.2017.5150
4) Schuhmacher A, et al. R&D efficiency of leading pharmaceutical companies - A 20-year analysis. Drug Discov Today. 2021 Aug;26(8):1784-1789. doi: 10.1016/j.drudis.2021.05.005.

Probability of success on the decline in most indications

PoS from Phase II to Phase III transition is below 30%

Probability of success

success rate = number that advanced to next phase/total number advanced & suspended



Overall clinical success rates in %



Sources: Scrip, Predicting Success: The Easiest, And Hardest Routes To Market, February 2021; BIO, QLS Advisors, Informa UK Ltd: Clinical Development Success Rates and Contributing Factors 2011–2020, February 2021.

Unique combination of precision platforms

Precision medicine is driving probability of success

Molecular patient databases

Re-defining health and disease via molecular disease profiles

Patient (iPSC) – derived disease models

- Modelling disease profiles using patient cells
- Comprehensive cpd profiling

Patient stratification and biomarkers

- Precision diagnostics
- Precise tracking of disease progression

Genomics – Transcriptomics – Proteomics – Metabolomics
Industrialised data generation

Data science – Machine learning / Artificial intelligence – Bioinformatics
AI/ML driven data analytics



Biological insights enable precision medicine

Transcriptomics and proteomics provide more biological insight than genomics

	Robustness	Scalability	Cost efficiency	Biological insight
Genomics 	●	◑	◑	◑
Transcriptomics 	●	●	●	●
Proteomics 	●	◑	◑	●
Metabolomics 	◑	○	○	◑
	Reproducibility • Day to day • Month to month • Year to year	Throughput • High • Medium • Low	Cost efficiency • High • Medium • Low	Molecular insights in • Cause of disease • Manifestation of disease • Organs, tissues, cells

EVO*panOmics* – High performance transcriptome and proteome analysis

Efficient data generation combined with superior data analysis increases PoS





Genomics	Standard process
ScreenSeq Transcriptomics	**High Performance Transcriptomics** • **Unprecedented throughput and sequencing depth**
ScreenPep Proteomics	**High Performance Proteomics** • **Unprecedented scale and protein coverage**
Metabolomics	Standard process

Predictive drug discovery – Evolving paradigm

- Seamless and cost effective platforms and processes
  - Patient from pre-clinic to clinic
- AI/ML driven data analytics
  - Available at all levels
- Connecting patient disease profiles to compound profiles
  - Ensures disease relevance and safety

Connecting complex clinical and pre-clinical data increases PoS

EVO*panHunter* – easy access to complex data analysis

Omics data
- Transcriptomics
- Genomics
- Proteomics
- Metabolomics

Clinical data
- Demographic information
- Medication
- Comorbidities

EVO*panHunter*
Data analysis



Meta data
- Gene/protein information
- Experimental parameters

Chemical data
- Structures
- Compound information
- Drug databases

More data
- Public knowledge
- BioMol databases, e.g. Wikipathways

Demand for PanHunter is accelerating exponentially

EVO*panHunter* – "…just the beginning"

Cumulative active users per month



We integrate AI/ML throughout the value chain

AI/ML driven drug discovery

Target ID/ validation | **Hit identification** | **Lead optimisation** | **Pre-clinical tox testing** | **INDiGO** | **Phase I** | **Phase II** | **Phase III** | **Market**

Multi-omics data analytics and compound profiling along the full value chain

EVO*gnostic*

(AI/ML derived signature generation)

AI/ML supported cell type annotation



Generative design[1)]



J.HAL℠ JUST – EVOTEC BIOLOGICS | J.DESIGN | E.INVENT-AI MOLECULAR DESIGN EXCELLENCE

Safety prediction

70% → 86% prediction improvement - DILI platform[2)]



Patient stratification



[1)] J.HAL is a GAN based AI-driven discovery platform, producing diverse human antibodies with broad efficacy features biased toward developability

[2)] Prediction are based on 2D Primary Human Hepatocyte assay with 128 reference compounds tested (largest reference compound data base reported), HCI: High content imaging, DILI: Drug induced liver injury

Predicting drug profiles will improve POS

Comprehensive Omcis data enables prediction of efficacy and safety

Reversal of disease signatures



Determination of MoA



Safety prediction



evotec

E.MPD

TRANSLATIONAL MOLECULAR PATIENT DATABASE

From patient data to discovery & stratification

“E.MPD re-defines patient populations according to disease mechanisms rather than symptoms. This paves the way for true precision medicine“

Uwe Andag / Christiane Honisch

Deep understanding of biology for precision medicine

The Evotec Molecular Patient Database (E.MPD)



EVO*panOmics*: Genomics, Transcriptomics, Proteomics and Metabolomics
EVO*panHunter*: Bioinformatics, AI/ML

Constantly fast growing unique human data source

The Evotec Molecular Patient Database (E.MPD) in numbers

# of patients

15,000+

# of samples

200,000+

# of data points generated so far

200 bn+

# of searchable data categories per patient in the E.MPD

50-500

# of clinically described diseases / etiologies in the E.MPD

30+/100+

# of targets from E.MPD in target validation & drug discovery

30+

Globally leading in kidney diseases

Overview/Example: >12,000 participants; >3,000 kidney biopsies

2018	2019	2020	2021	2022
• CKD & NephSyn • ~ 4,000 patients • ~ 900 kidney biopsies • Blood, serum & urine samples • Clinical records	• CKD (SKS) • ~ 2,000 patients • ~ 250 kidney biopsies • DNA, serum samples • Clinical records	• Healthy controls • 1,000 patients • 2,500 tissue biopsies • Kidney, liver, heart, serum • Clinical records	• CKD • ~ 5,000 patients • ~ 800 kidney biopsies • Blood, serum & urine samples • Clinical records	• NephSyn • ~ 300 patients • ~100 kidney biopsies • DNA, blood samples • Clinical records

https://www.nurturebiobank.org/
https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/salford-kidney-study/
https://www.gckd.de/; https://quod.org.uk/

SKS: Salford Kidney Study (CRISIS)
NURTuRE: National Unified Renal Translational Research Enterprise

CKD: Chronic kidney disease
NephSyn: Nephrotic Syndrome
QUOD: Quality in Organ Donation

Re-defining health and disease

Starting point for drug discovery, patient stratification & biomarker

>200,000 samples | **Billions of data points** | **EVO*panOmics* & EVO*panHunter*** | **Modality agnostic analysis** | **1st in class treatments**

Patient cohorts

- **Renal diseases**
- **Metabolic disease**
- **Other diseases**
- **Control groups**

Clinical data

Co-morbidities, Histology, Diagnosis, Organ function, Blood chemistry, Anthropomorphic

sc/snRNA-Seq, Transcriptomics, Proteomics, Metabolomics, Exome Seq, SNPs

Omics data





Accurate patient stratification

Transform clinical trial design & execution

Significant advantages over public domain data sets

Standard technology, data QC and rich data annotations to improve outcomes

		Public Domain	E.MPD TRANSLATIONAL MOLECULAR PATIENT DATABASE
Cohort planning/design	Physician engagement	○	●
	Prospective and longitudinal studies	◔	●
Clinical data	Sample ID linked to source data (e.g. hospital)	○	●
	Sample tracking (batch effects!)	○	◕
	Medical records	○	◕
	Evotec QC of medical record data	◔	●
	Number of annotations (age, sex, medication, comorbidities, …)	1-5	50-500
Analysis data	OMICS technology platform	several, no control	one, fully validated
	Availability of multi-omics data sets	◔	◕
	Data acquisition (sensitivity, sequencing depth, …)	◑	●
	Data comparability (combining cohorts)	◔	●

High quality data sources for increased probability of success

Superior signal-to-noise ratio on Evotec data compared to public domain data sets

Kidney cohorts



Cohort information and medical records

Public domain data

- No data QC info
- < 10 annotations
- No batch info

E.MPD TRANSLATIONAL MOLECULAR PATIENT DATABASE

- Data QC
- > 50 annotations
- Batch information





OMICS / sequencing data

Public domain data

- Several platforms
- One read out
- No batch info

E.MPD TRANSLATIONAL MOLECULAR PATIENT DATABASE

- 1 platform, QC
- Multi-omics
- No batch effects





Molecular profiling leads to deep understanding of diseases

Multi-omics analysis on patient samples

SNP analysis (DNA)

Polygenic risk score based on DNA analysis



Polygenic risk score estimating genetic predisposition for diabetes type 2

Transcriptomics (mRNA)

RNA sequencing to identify key driver and mechanisms of diseases



Proteomics (Proteins)

Proteomics analysis to confirm key mechanism on protein level



Clinical parameter

Integration of clinical records and histology



World-leading in high-throughput transcriptomics & proteomics processing and analysis

From bedside to bench and back to bedside

Example: Human target ID increases PoS

1

Patient serum proteomics analysis

Negative correlation of target abundance to kidney function (eGFR) in CKD patient serum



2

Rodent kidney transcriptomics

Healthy vs diseased rats: Target strongly up-regulated during disease





3

Kidney function

Knock-out mice with significantly improved kidney function in CKD



4

***In vivo* efficacy with therapeutic inhibitor**

Small molecule inhibitor suppresses kidney fibrosis in CKD



CKD: Chronic Kidney Disease
DKD: Diabetic Kidney Disease
KO: Genetic target knock out

E.MPD core component of alliances in CKD

CKD strategic drug discovery deals – "…just the beginning"

2016/17	2018/19	2020	2021	2022
• Upfront • Research funding • Milestones > € 300 m per product • Tiered royalties	• Vifor funded: € 25 m • 50% on all projects	• Upfront • Research funding • Milestones > € 150 m per product • Tiered royalties	• Upfront • Research funding • Milestones • Tiered royalties	• Upfront • Research funding • Milestones US$ 180 m per product • Tiered royalties

From Target identification & validation, via biomarker identification, to patient stratification

Accelerating changes in the healthcare paradigm

Omics based patient stratification, disease prevention and early intervention

Established diagnostics paradigm

Patient sees doctor only with symptoms

Doctor exams patient and makes initial diagnosis

Follow-up diagnostic tests (blood, urine)

Disease specific diagnostics

- Imaging
- Biopsy
- Histology

Too late Interventions

- Life style changes
- Medication and therapy
- Surgical interventions

Intervention
Disease Management

Omics driven personalised disease monitoring in the future

Healthy subjects with regular health checks

Health stratification by blood transcript-omics & AI/ML

Early detection of pre-dispositions and latent disease

- Disease prevention
- Less invasive treatment and Life style changes
- Prolonged life expectancy

Prevention - Health Management

World leading in blood transcriptomics

Deep insights into kidney disease

- E.MPD NURTuRE and GCKD cohorts for blood transcriptomics are unique in kidney disease:
  - by far highest sample numbers
  - extensive clinical data
  - most comprehensive molecular profiling based on blood transcriptomics
- No large-scale blood transcriptomic studies in the public domain

Blood transcriptomics at Evotec, # of blood samples



Public domain Evotec

OMICS-based patient stratification

A new way to define patient populations

Patients → **Blood** → **EVO*panOmics* & EVO*panHunter*** → **A map of health and disease**





Risk for disease and disease progression – Personalised disease monitoring

PoS: Probability of Success

EVO*gnostic* learning models (AI/ML) in kidney disease

Patient stratification and personalized disease monitoring

NURTuRE – patient cohort

AI/ ML used to assign disease CKD risk score to each patient

>2,000 CKD patients plotted according to CKD risk score





CKD risk score



CKD risk groups

Todays diagnostics paradigm of complex diseases, will be replaced by OMICS test

CKD: Chronic kidney disease

Disease insights down to the single cell level resolution

EVO*gnostic* AI/ML tools in kidney disease

>2,000 CKD patients plotted according to CKD score



Risk Groups



Genetic predisposition adds an additional layer for prevention

Predisposition for disease/phenotype based on genetics

Genomics

Genetic predisposition determined for >5,000 CKD patients



Patients with genetic predis-position show higher risk of developing disease



Genetic predisposition combined with CKD risk score to increase diagnostic test precision

Source: PGS (polygenic risk score) Catalog – https://www.pgscatalog.org/; GWAS Catalog – https://www.ebi.ac.uk/gwas/

E.MPD expansion will accelerate multiple therapeutic areas

Selected key events to watch out for

E.MPD
TRANSLATIONAL MOLECULAR PATIENT DATABASE

Kidney diseases

- Access to selected kidney disease etiologies
- Prospective longitudinal studies
- Pre-disease / early stage disease cohorts

Liver disease

Inflammation

Fibrosis

- Access to NAFLD, NASH & liver fibrosis patient cohorts
- Add metabolic disease / diabetes cohorts
- Access to inflammatory & autoimmune disease cohorts

Oncology

Neuro-inflammation

Infectious Diseases

- Access to samples and data in the oncology & neuroinflammation space
- Studies for effective treatment monitoring in tuberculosis
- Cohort studies to understand and conquer Long COVID

evotec

iPSC Drug Discovery

iPSC drug screening to end erratic target selection

“iPSC-based drug screening enables identification of novel, highly disease-relevant targets.“

Nele Schwarz / Cord Dohrmann

iPSC drug discovery platform in numbers

Selected KPIs

# of patient derived iPS cell lines	**# of iPSC-derived cell types**	**# of iPSC-derived cells per year**
300+	**15+**	**500 bn+**
# of drug discovery programs	**# of cpds screened per year**	**First molecule in the clinic**
20+	**1.0 m+**	**EVT8683**

iPSC technology shifts drug discovery paradigm

Focus on disease relevance



Figure adapted from DOI: https://doi.org/10.1016/j.molmed.2020.09.013

>15 cell types, co-cultures and organoids established

Development of iPSC drug discovery platform

2013



2014



2015





2016







Co-culture:
neurons
+ astrocytes

2017





2018





2019







Triple-culture:
neurons
+ astrocytes
+ microglia

2020





2021







2022









What is next?

- T-cells
- Skeletal muscle
- Hepatocytes
- Liver organoids
- Brain organoids
- ….

Nephron-on-a-chip



Unbiased identification of relevant drug candidates

Screening to revert molecular patient profiles to the healthy state

EVO*panOmics*

Data generation

- Patient-derived *in vitro* disease model
- High-throughput screen
- Transcriptome analysis in 384 well format



EVO*panHunter*

Data analysis

- Identifies most suitable chemical hits
- Focus on reversal of molecular disease phenotype
- Weed out unwanted mechanisms

Transcriptome profiles induced by individual compounds in patient-derived cellular disease model



iPSC already highly productive, …"but just the beginning"

Continuous expansion of disease models and programmes

evotec & Bristol Myers Squibb™

iPSC neurodegeneration

- Development of novel therapies for a broad range of diseases
- First programme EVT8683 (eIF2b activator) in clinics



iPSC platform shifts drug discovery & cell therapy paradigms

Holistic approach to identification of novel therapeutic options

DRUG DISCOVERY

Neurodegeneration, Neuroinflammation & Neurodevelopmental Diseases
Cortical neurons, Microglia, Astrocytes, Oligodendrocytes, Cortical neurons

Lysosomal Storage Diseases
Cortical neurons, Astrocytes, Microglia, Macrophages

Chronic Kidney Disease
Podocytes, Proximal tubular epithelial cells, Glomerular endothelial cells

…more TA[1] to come



CELL THERAPY

Diabetes
Beta cells

Immuno-oncology
Natural Killer cells, T-cells, Macrophages

Cardiac & Heart Failure
Cardiomyocytes

Retinopathies
Retinal pigment epithelial cells

New

CUREXSYS PURE TO CURE · Bristol Myers Squibb™ · CHDI FOUNDATION · QRbeta THERAPEUTICS · Boehringer Ingelheim

1) Treatment areas

AMD – a global pandemic affecting ~200 million people

High disease prevalence coupled with huge unmet medical need

- **People effected to rise to 288 million by 2040**
  - Major cause of blindness in developed world
- **Current treatment options severely limited**
  - Wet AMD (~10% of cases):
    - **anti-VEGF intravitreal injections:** High risk infections, intraocular inflammation, possible retinal detachment, short period of effectiveness
    - **Laser coagulation/photodynamic therapy:** Permanent destruction of the retina, decreasing vision
  - Dry AMD (~90% of cases): **none**

Age-related macular degeneration in the world



Adapted from https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70145-1/fulltext

A complex, challenging eye disease

Age-related macular degeneration (AMD)

- **Pathogenesis**
  - Progressive disease with loss of vision in center of visual field (macula)
- **Challenges**
  - No predictive *in vitro* models and *in vivo* models
  - Strong genetic heterogeneity
  - No genetic disease link
- **Opportunity**
  - Vast majority of drugs in clinic and clinical trials target wet AMD
  - Only two drugs in late-stage clinical development
  - Great scope to develop compounds for all stages



Taking human iPSC-based drug discovery to a new level

Biologically relevant translational iPSC models combined with innovative platforms

Phenotypic screening rule of 3[1)]

- **System – HUMAN**
  - High relevance to human disease at screening stage
  - Replacement of rodent cell & *in vivo* models
- **Stimulus – RELEVANCE**
  - Intrinsic disease-specific pathophysiology
  - Biologically relevant trigger
- **Readout – TRANSLATIONAL**
  - Functional manifestation of disease
  - Potential for patient stratification
  - *In vitro* trial “in a dish”



[1)] Vincent et al. (2015) ScienceTransMed 7, (293), 293ps15

Predictive cell models to target retinal cell function & cure AMD

Better strategy to develop therapies

iPSC-derived retinal cells



- Unbiased phenotypic screening to identify new targets driving processes towards retina protection

Phenotypic screening



- Assay system with high translatability to clinical setting (cell system and trigger as close as possible to disease of interest)
- Screenable assay format (robust and reproducible)

EVO*panOmics*



- Highly diverse compound set for screening
- AI hit selection to efficiently maximise screening potential
- Leveraging Evotec's panomics platform to enable target deconvolution strategies

Novel AMD Targets



- Identification of novel targets to develop first in class therapies for AMD

https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-ipsc-based-drug-discovery-partnership-with-boehringer-ingelheim-in-ophthalmology-6136

AMD: Age-related macular degeneration

Leading proprietary platforms drive partnership

Another step towards precision medicine



evotec

#RESEARCHNEVERSTOPS

NEWS RELEASE, 25 JANUARY 2022

EVOTEC ENTERS IPSC-BASED DRUG DISCOVERY PARTNERSHIP WITH BOEHRINGER INGELHEIM IN OPHTHALMOLOGY

- *PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS*
- *AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS*

Hamburg, Germany, 25 January 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell ("iPSC")-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions.

Through phenotypic screening of human iPSC-derived cells, supported by Evotec's PanOmics platform, Evotec will identify small molecules able to modulate disease phenotypes, and then validate the underlying promising targets for potential therapeutic interventions. Boehringer Ingelheim will then continue with the discovery and development of potential therapeutic candidates. Besides an undisclosed upfront and FTE-based research payment, Evotec will continue to benefit from the successful further development of the candidates in the form of milestones and layered royalties.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to utilise our unique iPSC- and PanOmics-based approaches to ophthalmologic diseases in this new partnership with Boehringer Ingelheim. Phenotypic screening approaches have a long history of delivering highly effective drugs based on novel molecular mechanisms. Phenotypic screens based on human iPSC-derived disease models combined with our unbiased PanOmics readouts are more likely to deliver disease relevant drugs than any other cell-based screening approach."

Boehringer Ingelheim

evotec

- iPSC platform in combination with **EVO***panOmics*
- Identify and validate new approaches for ophthalmology
- Upfront, FTE-based research payment, milestones and layered royalties

AI /ML specific application

Drug induced liver injury (DILI) prediction

“Advanced human relevant cell models combined with omic-technologies is transforming safety assessment.“

Paul Walker

AI/ML application: Drug induced liver injury (DILI) prediction

Transcriptomics safety database (**EVO***panOmics*) & AI (**EVO***panHunter*)

Building AI/ML knowledge in many safety areas



Organ safety expansion	Transcriptomic database in e.g. DILI, cardiotoxicity and teratogenicity, utilizing iPSC capabilities
***In vivo* toxicology**	Pre-clinical species high throughput transcriptomics to evaluate >15 organs including blood
Drug toxicity mechanism	Comprehensive tool box continued developed to interrogate toxic mechanism of action
AI/ML expansion	Safety data to build expansive database and aid drug design

Toxicity – leading source of drug attrition

Example: AI/ML application – Drug Induced Liver Injury (DILI) prediction

Drug Induced Liver Injury (DILI)



Transcriptomics and AI/ML to proactively de-risk tox liabilities in integrated drug development

only

50%

DILI picked up in animals

18%

withdrawals from market caused by DILI

Martignoni, et al. Expert Opin Drug Metab Toxicol, 2006. 2(6): p. 875-94.
Olson, et al., Regul Toxicol Pharmacol, 2000. 32(1): p. 56-67.
Siramshetty, et al., Nucleic Acids Res. 2016 Jan 4;44(D1):D1080-6.
Onakpoya, et al., BMC Med. 2016 2;17(1):56.

Largest DILI transcriptomic database in the world ….and growing

Safety database creation

Partners compounds

Improving sensitivity and specificity of safety prediction

Understanding mechanism of toxicity

AI/ML DILI database



LTKB Data base

1,372 FDA DILI assigned compounds

1,603 Marketed compounds

Mechanistic compounds & drug properties

DILI Prediction

DILI risk



Mechanistic information



Similarity profiles



LTKB: Liver Toxicity Knowledge Base

Turning transcriptomic data into DILI prediction using AI

The largest DILI transcriptomic database at work

High risk



Low risk



DILI probability threshold

Low risk



High risk



This representation of the workflow is simplified

EVO*panOmics* & EVO*panHunter* deliver superior DILI prediction

Gold Standard High Content Imaging vs. EVO*panOmics* & EVO*panHunter*

Current gold standard: Image based DILI platform[1)]

- Primary human hepatocytes
- High content imaging – Seven read-outs



2D PHH

Prediction accuracy

70%

16%

Evotec's new DILI prediction platform[1)]

- Human Liver Microtissues (hLiMTs)
- High-throughput Transcriptomics



3D hLiMT

Prediction accuracy

86%



[1)] Prediction are based on matched 2D Primary Human Hepatocyte assay or Human Liver Microtissues (hLiMTs) with 128 reference compounds tested (largest reference compound data base reported)

Future of safety prediction is Omics-driven

Robust human relevant cellular models combined with HT-Omics

Relevant cellular models

Organotypic models & HT transcriptomics



Toxicity type

- Hepatic
- Cardiovascular
- Haematological
- Neurological
- Multiple
- Dermatological
- Carcinogenicity
- Renal
- Respiratory
- Reproductive

Safety database



Safety liability prediction

DILI risk

Mechanistic information



Similarity profiles



Short Break – Q&A

Agenda

Action Plan 2025 update
"…just the beginning" of the data-driven R&D Autobahn to Cures

Precision technologies bring PoS up
From molecular databases via iPSCs, to AI/ML tools at work

Processes bring PoS up
From targets, via full suite of AI/ML tools, to manufacturing

Roundup & Q&A session



evotec

E.RNA

TARGETING RNA SPACE

Matching technology with modality

“Drug targeting is my bread and butter, targeting RNA is the luscious topping.“

Steffen Grimm

Proprietary platform drives high value partnerships

Another step towards precision medicines

evotec

#RESEARCHNEVERSTOPS

NEWS RELEASE, 22 MARCH 2021

EVOTEC AND TAKEDA ENTER STRATEGIC RNA TARGETING DRUG DISCOVERY AND DEVELOPMENT ALLIANCE

- *EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM AGAINST MULTIPLE RNA TARGETS ACROSS TAKEDA'S KEY INDICATIONS*
- *EVOTEC RECEIVES RESEARCH FUNDING AND IS ELIGIBLE FOR SUCCESS-BASED MILESTONES AND TIERED ROYALTIES*

Hamburg, Germany, 22 March 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited ("Takeda") with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda's research and development areas. The collaboration will leverage Evotec's extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.

Under the terms of the agreement, Evotec will receive significant research funding and will be eligible to receive discovery, pre-clinical, clinical, commercial and sales milestone payments of up to US$ 160 m per programme. Additionally, Evotec is entitled to tiered royalties on net sales of any products resulting from the collaboration.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Many highly validated targets have proven to be intractable via conventional protein targeting approaches. For this reason, Evotec has been pioneering RNA targeting strategies and approaches for quite some time. We are very excited about the opportunity to collaborate with Takeda in this field as both companies share the vision to jointly develop small molecule therapeutics against high value RNA targets that will deliver long awaited therapeutics."

Takeda

evotec

- Extensive RNA targeting platform to optimally identify RNA sequences to target small molecule ligands
- Research funding, pre-clinical, clinical, commercial milestones of US$ 160 m per programme and high royalties

One of the most comprehensive platforms in the industry

Key indicators

# of active targets

15+

# of scientists in two largest collaborations in next 3 years

80+

 # integrated technologies in RNA targeting platform

>20

# of completed RNA target specific binder screens

28+

 # people involved on RNA projects this month

~45

Relevant players in the field

~ 5 - 10

Almost limitless future of RNA targets

Expanding the drug target space

Looking beyond the undruggable proteins (mRNAs) as the target species

Targeted genome



- Druggable “genome” bigger than druggable “proteome”
- Minor subset of DNA is translated into druggable proteins (~3%)
- Non-druggable proteins and non-coding RNAs targeted on the RNA-level

Functionally characterised lncRNA



Applying multiple modalities with new target biology

Strengthening offering for drug discovery

Antisense (ASO) and Interfering RNA (siRNA)
Oligonucleotide therapeutics – sequence targets



Up or Down regulation of RNA target

Small molecule
Structural targets



Alter maturation, translation, location, degradation of RNA

SM image adapted from: *Nat Rev Chem* **4**, 441–458 (2020).

Recognizing RNA as druggable molecule

Examples of drug like molecules specifically targeting RNA

- Small molecules substances can be developed into potent and therapeutically active RNA-drugs
- Example: Ribocil, which binds to a structural “pocket” in their target RNA with high affinity and selectivity

Ribocil
(Target: bacterial multihelix junction mRNA)





RNA binders show “chemical beauty” *(follow Lipinsky’s rule of five, have high QED scores, low total polar surface areas consistent with good membrane permeability and neither contains red flags for toxicity)*

Warner KD et. Al. (2018) Nature reviews DD 17, 547-558.

Our platform makes RNA targeting possible

Thinking in tool boxes of technologies

Structural model tool box

Research informatics	***Ab initio* prediction**	**Consensus ALGORITHM** 
Structure biology	**NMR** **SAXS** **LC-MS**	
Probing technologies	**SHAPE** **COMRADES**	

Molecular dynamic simulation to derive structural ensemble

Biological Validation Tool Box

***In vitro* Biology**	**Construct design & validation**	
	Reporter assay	
	Interactome	
Hit ID	**Technical feasibility assay cascade**	

Validation of functional element

NMR – Nuclear Magentic resonance / SAXS – Smal Angle X-ray Scattering / LC-MS – Liquid Chromatography – Mass Spectrometry / SHAPE – Selective 2'hydroxyl acylation analysed by primer extesnsion / COMRADES – Cross linking of matched RNA and deep sequencing

Bringing technology and experience together

RNA biology core strengths



Our RNA platform is industry leading

Benchmarking against the leading platforms

	Competitor 1	Competitor 2	Competitor 3	E.RNA TARGETING RNA SPACE
RNA production				
RNA structure analysis				
Screening throughput				
RNA CMPD library				
***In vitro* / *in vivo* cascade**				
IND capacity				

Illustrative assessment of capabilities

Our RNA platform in action

Affinity, structure , therapeutic effect

Validation and hit profiling with selective binders

Stability changes of RNA



Influence on RNA conformations by selective binders

Overlay unbound and bound RNA



Teal = RNA
Orange = RNA::cpd 1:1 ratio

In cellular target engagement of selective binders and effect on pathway

In cell assays and tox assessment



Best series entered H2L phase

Partnerships/Alliances

Ongoing and upcoming projects currently planned/running

RnD Collaborations	1	Takeda	>10 targets	ImmunOncology, rare disease	SM	• First targets entering Hit ID
	2	Not disclosed	>5 targets	Oncology, CNS	SM	• Cellular active cmpds showing SAR
	3	Not disclosed	2 targets	Oncology	SM	
	4	CHDI	1 target	CNS	SM	
	5	Amgen	1 target	Metabolic disease	siRNA	• LO phase
	6	ResalisTx	1 target	Metabolic disease	ASO	• IND phase
Innovate	7	Evotec	2 targets	Antiinfectives / Antivirals	SM	• Cellular active cmpds showing SAR
	8	Evotec	1 target	Oncology	SM	• Cellular active cmpds showing SAR
	9	BMS	1 target	CNS	ASO	
Equity share / spin offs	10	Not disclosed	>5 targets	Oncology	SM	• First targets entering Hit ID
	11	Not disclosed	2 targets	Age related disease	SM	

Wide open space to be conquered

Next actions to watch

E.RNA
TARGETING RNA SPACE

Maturation of RNA platform	Enabling launch of additional target classes and advance product pipeline
RNA degraders	Develop proprietary chimeric degrader molecules (“RiboTac”)
Fuse small molecules and mRNA therapeutics	Introduce switchable RNA translation for mRNA therapeutics using small molecules

evotec

E.INVENT-AI

MOLECULAR DESIGN EXCELLENCE

Full suite of AI and advanced computational tools

“The intersection of quality data generation, AI/ML exploitation and deep domain know-ledge is our sweet-spot of highest performance.“

Craig Johnstone

Generative and predictive tools in daily use

AI/ML applications at work – E.INVENT-AI

# of Downloads



20,000
in 2 months

# of predicted datasets

7,392

Average time saved

>35%

# of PubMed articles mined using Natural Language Processing

29.1 m

# of E.INVENT-AI users

>400

 # patent applications in last 24 months

62

Cost-effective and rapid progression to clinic with higher PoS

Essential components for high-performance discovery and development



- Expert drug hunting, problem-solving & decisions
- Cutting-edge AI/ML technologies
- Disease biology with translational focus

E.INVENT-AI and drug design infrastructure is world leading

Benchmarking against leading SMol technology companies

	Competitor 1	Competitor 2	Competitor 3	E.INVENT-AI MOLECULAR DESIGN EXCELLENCE
Generative AI tools	●	◕	◕	◕
Proprietary prediction & selection methods	◑	◑	◕	●
Infrastructure for high volume data generation	◔	◔	◑	◕
Protein structure and SMol 4D conformation	◑	◑	◑	●
Comprehensive *in vitro* / *in vivo* cascade	◔	○	◔	●
Developability pre-dictions & capabilities	○	○	○	●

Illustrative assessment of capabilities

E.INVENT-AI: Full suite of AI and advanced computational tools

Comprehensive AI/ML toolkit for design

AI-driven generative tools
Molecular autoencoders, SLERP, virtual expansion

Predictive models
Streamlined ML models – global and local models for virtual selection / filtration

Transforms
Molecular optimisation using coded expert medchem transformations

Bayesian Optimisation
Design for model construction and optimsation

Matched molecular pairs
Prediction of properties using statistical historical data



Protein and SMol structure exploitation
CryoEM, MD, FMO, 4D NMR conformational analysis

Generative AI, prediction tools, experimental techniques and drug hunting expertise create state-of-the-art design

Data and experience across entire value stream

Rapid learning iterations through the drug discovery process



Rapid identification of problem and generation of solutions

Example: Combining SM generative design & drug hunting expertise to target nerve exposure

“Do we have a candidate?”

Detailed EVT profiling revealed

- **Potent (pIC50 8)**
- **Predicted human dose = 1.2g**
- **Safety findings (CNS)**

“Can we find way forward?”

- **Strategy:** Use data package (~30 compounds) & global data to build predictive models
- Bias design space with EVT MPOs (nerve, anti-CNS)
- Application of E.INVENT-AI design (Bayesian Optimisation, and AI/ML ADMET models)

Solution: Bayesian Optimisation directed exploration to Series 1b; combining desirable potency, diminished CNS exposure and desirable nerve permeation



Series 1b ‘Cmpd 2’

- **pIC50 = 7.2**
- **Nerve Kp,uu = 1.5**
- Brain Kp,uu = **0.3**
- **eDtM = 950 mg**



5 months

New Series - improved disposition between brain & nerve

2021 EFMC International Symposium on Medicinal Chemistry: **APPLICATION OF ARTIFICIAL INTELLIGENCE ON A DRUG DISCOVERY PROJECT: AN EVOTEC INSIGHT**
F. Palazzesi, M. Brunavs, N. Monck, R. Rathmell, A. Davenport, D. Hristozov and A. Pozzan

Efficient invention of quality candidate in 350 compounds

Example: Project progression as a function of iterative design

Target X Inhibitors



Progression and Outcome

1. First data package. **High eDtM and safety issue**
2. Bayesian Optimisation and E.INVENT-AI directed exploration to Series 1b: Improved safety, **high predicted dose (eDtM)**
3. Precision design on conformation identified Series 1c: provides nerve exposure and exclusion from CNS
4. Optimisation of eDtM and **holistic assessment of drug quality**
5. Candidate '5':
   - **pIC50 = >8.5**
   - **Nerve Kp,uu = 0.7**
   - **Brain Kp,uu = <0.05**
   - **eDtM = <10 mg**



Combining AI/ML with drug hunter knowledge created high quality asset in 11 months, 350 cmpds, with high efficiency

MPO = multi-parameter optimisation
eDtM = Early Dose to Man
BO = Bayesian Optimisation

Just-Evotec Biologics

From J.HAL to J.POD

Successful Execution

“We are successfully executing on our mission to design and apply innovative technologies to dramatically expand global access to bio-therapeutics. AI/ML/NLP driven technologies provide the foundation.“

Linda Zuckerman

Successful execution in numbers

Selected key indicators

J.PLANT's 3-Year Success rate

100%

Longest Perfusion Culture in days

>24

J.HAL library projected diversity (2022)

60 bn Fabs

Kg of mAbs against an infectious disease target from 2 500L Runs

18 & 18,3

# of consecutive successful runs (since 2019)

22

Highest productivity in a 500L Continuous Perfusion Bioreactor in g mAb / L / day

3.5

Enabling global access to modern biologics

Example: Efficient and flexible biologics manufacturing (**EVO***access*)



Large and diverse library to generate antibodies

J.DISCOVERY™ MOLECULE DISCOVERY

J.HAL℠ AI DESIGNED MAB LIBRARY

J.DESIGN

J.MD™ MOLECULE DESIGN

Reviews and improves native antibody sequences to enhance manufacturabiliy

JP3® PROCESS & PRODUCT DESIGN

Disruptive, intensified production process from few kilograms to metric tons in one facility

J.POD® MANUFACTURING DESIGN

Modular, flexible "PODs" with most capital efficient set-up

Partners

MERCK

JPEO-CBRND

BILL & MELINDA GATES foundation

OncoResponse

ology BIOSERVICES

ABL inc. ADVANCED BIOSCIENCE LABORATORIES

A quality solution at every stage of biotherapeutic development

From sequence discovery to vial

J.DISCOVERY™ — Molecule Discovery

Alloy Therapeutics

HTS Hybridoma



Phage Display

Human mAb

J.HAL℠ — AI Designed mAb Library

Ig/VHH Discovery



Human mAb

Existing mAb



B-Cell Sequence Panel

EVQLQE … VEIKR
QVQLQQ … VEIKR
QVQLVE … VEIKR

J.MD™ — Molecule Design

Abacus™
In sillico Design Tool

RANDŸ
ML Stability Prediction & Rank Order by **NLP**



Process Development Information

JP3® — Process & Product Design

Partner Cell Line

JP3® — Process & Product Design



Rapid, cost-effective mAb characterization and process development

CL-72

Just Proprietary Cell Line/ Vector System

J.POD® — Manufacturing Design

J.POD® — Manufacturing Design

Modular, automated GMP manufacturing of drug substance

Partner Just – Evotec Biologics

DNA to IND to Commercialization

Benchmarking against the leading platforms

	Competitor 1	Competitor 2	Competitor 3	Just-Evotec Biologics
Antibody discovery with CMC readiness				
Integrated Discovery, Pre-clinical, CMC, Clinical				
Low-Cost Commercial Manufacturing				
Mature Continuous Platform				
Complex Molecule Product Quality				
Rapidly Deployable Flexible Capacity				

Illustrative assessment of capabilities

Abacus & RANDŸ lead to the best candidate mAbs

Example: From sequence discovery to vial

J.DISCOVERY™ MOLECULE DISCOVERY — J.MD™ MOLECULE DESIGN — JP3® PROCESS & PRODUCT DESIGN — J.POD® MANUFACTURING DESIGN

<1 month for characteriz. | <5 months to cGMP start

B-Cell Sequence Panel

EVQLQE … VEIKR

QVQLQQ … VEIKR

QVQLVE … VEIKR

Abacus & RANDŸ NLP developability assessment and optimization



Prioritised 49 sequences with **Ab**acus and RANDŸ

Top 4 sequences: Multi-attribute Mass (MAM) Spec and Biophysical Analysis

Best 2 mAbs into JP3 Process & Product Design



cGMP manufacturing

Partner | Just – Evotec Biologics

Rapid progress to cGMP start

Example: AI/MD **Ab**acus and RANDŸ enabled rapid cGMP start

J.DISCOVERY™ MOLECULE DISCOVERY — J.MD™ MOLECULE DESIGN — JP3® PROCESS & PRODUCT DESIGN — J.POD® MANUFACTURING DESIGN

<5 months to cGMP start

Best 2 mAbs into JP3 Process & Product Design

Cells	**PD Robotics**	**Scale-down Systems**	
			
2 RCBs of pools	Cloning both mAbs	Process & Pro-duct Design	cGMP Start
Optimized media, host, vectors	HTS Screening Single round of cloning	Intensified connected processing High resolution analytical meth-ods in real time	

Continuous harvest outperforms fed batch by 10x

Example: Perfusion and continuous manufacturing compared to traditional fed batch

Viable Cell Density (10e6 cells/mL)



- 3L model system gives high confidence in scale-up
- High productivity: 3–4 grams product / L / day

Comparison of 1 x 500L Run, in kg DS per 500L Bioreactor



- Total of 18kg and 18.3kg to date (5 x 500L runs)
- Extending culture duration to 15 day increases mass produced

3L Model 500L continuous manufacture 500L fed batch

Fully E2E continuous process outperforms fed batch 20x

Example: More intensification, higher productivity, lower COGMs

Fully E2E continuous process for late-stage products (> 25-day production)





Global manufacturing network is “…just at the beginning”

J.POD® – Current status and timings

J.DISCOVERY™ MOLECULE DISCOVERY — J.MD™ MOLECULE DESIGN — JP3® PROCESS & PRODUCT DESIGN — J.POD® MANUFACTURING DESIGN

J.PLANT
Seattle, WA

- 500L SUB
- Ph1 – 2 Clinical
- Over 34 runs
- 100% success 3 years

J.POD-1
Redmond, WA

- 500L & 1,000L SUB
- Ph1 – Commercial
- First cGMP run Oct 2021

J.POD-2
Toulouse, France

- 500L & 1,000L SUB
- Ph1 – Commercial
- Groundbreaking 2022
- CQV 2024



Robust growth fueled by successful execution

Forecast revenue for J.POD in Redmond, WA (USA)

Outlook of revenue for J.POD in Redmond, WA (USA)



- J.POD-1 Redmond, WA, (USA)
  - expansion and build-out towards optimal efficiency
  - 2024 full commercial readiness anticipated
- J.POD-2 Toulouse, France (EU)
  - ground-breaking in 2022
  - operational in 2024

Agenda

Action Plan 2025 update
"…just the beginning" of the data-driven R&D Autobahn to Cures

Precision technologies bring PoS up
From molecular databases via iPSCs, to AI/ML tools at work

Processes bring PoS up
From targets, via AI/ML tools, to manufacturing

Roundup & Q&A session



“I have spent my career as a scientist and consultant in life sciences on the confluence of biology, chemistry, and technology more broadly, i.e., data, A.I./ML as well as automation. Evotec’s platform is uniquely positioned to capitalize on this opportunity as we enter a new era of science and disease understanding.“

Matthias Evers

Matthias Evers new Chief Business Officer

Portrait

- **PhD molecular biochemist and bioinformatician**
- **20 years of experience as Senior Partner of McKinsey & Company** helping R&D organizations globally to excel at innovation through large-scale performance transformations, innovation programs, and novel approaches for maximizing value from new assets, capabilities and technologies
- Areas of expertise include designing and supporting full-scale R&D transformation programs, designing and developing digital and analytics solutions to support medical education and engagement, and supporting to pursue excellence in core functions such as drug discovery and medical regulatory affairs
- Advisor and speaker at high-profile science events, including the **Lindau Nobel Laureate Meetings and Global Biotech Revolution's GapSummit** for young researchers and academia

Setting the pace to accelerate growth along Action Plan 2025

Selected key events to wach 2022

R&D efficiency platforms	• Undisrupted growth in line with AP 2025; Continued double digit growth of base business (**EVO***iR&D)* • Significant capacity and value chain expansion for all modalities and sites
Precision medicine platforms	• New strategic partnerships, important milestones, and expansions of co-owned alliances; Multiple clinical trial initiations and progression of co-owned pipeline; (**EVO***royalty)* • Spin-Offs and investments along Building Blocks of AP 2025 (**EVO***equity*)
Just – Evotec Biologics	• Start of production J.POD® Redmond, WA (USA); Start of construction J.POD® Toulouse, France (EU) • Multiple New partnerships (**EVO***access*)

evotec

#RESEARCHNEVERSTOPS

Many thanks for your participation!

evotec

#RESEARCHNEVERSTOPS

QUESTIONS AND ANSWERS